Blog
RSS FeedPosted by Michael Wonder on 03 Jul 2018
NICE says Tookad too expensive for prostate cancer
3 July 2018 - The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not ...
Posted by Michael Wonder on 28 Jun 2018
NICE backs Roche’s Alecensa
28 June 2018 - Roche’s Alecensa has won NICE backing as a treatment for a rare type of lung cancer, ...
Posted by Michael Wonder on 07 Jun 2018
The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer
6 June 2018 - The Institute of Cancer Research, London, has expressed disappointment that the prostate cancer drug abiraterone (Zytiga) ...
Posted by Michael Wonder on 06 Jun 2018
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer
6 June 2018 - It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy and prednisone/prednisolone will become routinely ...
Posted by Michael Wonder on 06 Jun 2018
Life-extending lung cancer drug will be more widely available on the NHS after NICE review
6 June 2018 - NICE says more people should be able to freely access pembrolizumab, known as Keytruda, after a new ...
Posted by Michael Wonder on 05 Jun 2018
NICE rules against first-line use of Ipsen’s Cabometyx
5 June 2018 - NICE has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on ...
Posted by Michael Wonder on 03 Jun 2018
Tesaro's ovarian cancer drug Zejula added to Cancer Drugs Fund
1 June 2018 - Tesaro's ovarian cancer drug Zejula (niraparib), the first PARP inhibitor shown to be effective in patients ...
Posted by Michael Wonder on 31 May 2018
NHS cancer nurse who crowdfunded her own cancer drug treatment thanks donors for extending her life
31 May 2018 - ‘I would love all drugs to be available on the NHS but it is not a bottomless ...
Posted by Michael Wonder on 31 May 2018
Pfizer's Xalkori makes it onto Cancer Drugs Fund
31 May 2018 - NICE has published draft guidance recommending that Pfizer's Xalkori (crizotinib) to treat ROS1-positive advanced non-small-cell lung ...
Posted by Michael Wonder on 27 May 2018
NICE issues decision on Mylotarg, Besponsa for leukaemia
25 May 2018 - NICE has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid ...
Posted by Michael Wonder on 17 May 2018
NICE backs Roche’s Tecentriq for pre-treated bladder cancer
17 May 2018 - Roche’s Tecentriq will be routinely available on the NHS in England and Wales to patients with ...
Posted by Michael Wonder on 05 May 2018
Hundreds of people with blood cancer given more treatment options after NICE recommends three drugs
4 May 2018 - NICE has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on ...
Posted by Michael Wonder on 05 May 2018
Long term benefit of neuroblastoma treatment is too uncertain, says NICE
4 May 2018 - NICE has published draft guidance in which dinutuximab beta is not recommended as a treatment for high-risk ...
Posted by Michael Wonder on 30 Apr 2018
Final NICE nod for Keytruda in bladder cancer
30 April 2018 - MSD’s Keytruda has become the only immunotherapy to be funded by the NHS for the treatment ...
Posted by Michael Wonder on 11 Apr 2018
Use of Merck's Bavencio (avelumab) on NHS supported by NICE
11 April 2018 - Draft final guidance proposes different access streams for first-line and second-line use in patients with Merkel ...